FDA review is still unforgiving when the file logic is weak.
The recurring issue is not usually a total absence of work. It is that the package contains data, endpoint language, and conclusions that do not form one coherent biological evaluation argument around the finished device.
Many teams still assume FDA biocompatibility problems come only from missing tests. In practice, avoidable AI requests often come from weak file logic: a disconnect between device description, contact profile, chemistry, endpoint rationale, and final conclusions.
What Still Triggers Questions Most Often
- Device representation is blurry: the file does not make it easy to understand what actually contacts the patient, for how long, and in what finished state.
- Chemistry is present but disconnected: extractables, leachables, or compound tables exist, but they are not translated into usable endpoint or toxicological conclusions.
- Endpoint logic looks copied: the matrix appears complete, but the rationale still feels generic rather than device-specific.
- Waivers are asserted too quickly: existing data may be directionally useful, but the justification for avoiding new work is not developed enough.
- Residual-risk language is too soft: the conclusion sounds confident without showing why the evidence truly supports it.
What Reviewers Usually Need to See More Clearly
- A clear finished-device framing: not only raw materials or components in isolation, but the actual patient-contacting device configuration.
- A usable contact profile: nature and duration of contact should support the endpoint logic without contradictions.
- Chemistry-to-risk translation: when chemical characterization is central to the argument, the file should show how it affects endpoint conclusions and residual risk.
- Selective testing logic: why some work was needed, why other work was not, and how those choices relate to the overall evidence package.
Where Teams Still Lose Time
- Too much rewriting too late: active pressure leads to broad edits instead of targeted correction of the true weak points.
- BER, chemistry, and summary drift apart: each part may be individually reasonable, but together they do not read as one integrated position.
- Testing is used as a substitute for argument quality: more data is gathered without clarifying how it will solve the core weakness.
What to Pressure-Test Before Submission
- Does the device representation match the real finished article under review?
- Do the endpoint decisions still make sense for the current materials, manufacturing state, and contact duration?
- Is the chemistry section actually influencing the biological evaluation conclusions?
- Would an outside reviewer understand why each waived or completed endpoint was handled that way?
- Is the summary resolving ambiguity, or merely restating it more neatly?
If the file already exists, the best first step is usually not a full rewrite. It is a focused review that identifies exactly where reviewer friction is most likely to occur.
Key References
- FDA biocompatibility guidance for medical devices and recognized consensus standards
- ISO 10993-1 biological evaluation framework
- ISO 10993-17 and ISO 10993-18 where chemistry and toxicological reasoning drive the file
- Current FDA-facing review patterns reflected in AI-response remediation work
If the package already exists, start with the weakest part before rewriting the whole thing.
A focused review is usually the fastest way to see whether the current FDA-facing biocompatibility logic is usable, weak, or likely to trigger avoidable reviewer friction.